Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SANA
STRONG SELLSana Biotechnology, Inc. · Healthcare · United States · $885M · Avg Vol: $11M/d
COMPANY DESCRIPTION
Sana Biotechnology, Inc. is a clinical-stage biotechnology company focused on creating and delivering engineered cells as medicines for a range of challenging diseases. The company's competitive moat lies in its innovative gene and cell engineering platforms, aiming to develop both *in vivo* and *ex vivo* cell therapy approaches. Sana is a high-growth potential player in the cutting-edge field of cellular and gene therapies, targeting unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.14 | -1.43 | -1.46 | -1.16 | -0.96 | — | -0.92 | -0.58 | -0.52 | — |
| Shares | — | 191.0M | 197.9M | 223.9M | 266.7M | +39.6% | 278.3M | — | — | — |
| Debt | — | 108.3M | 104.1M | 94.2M | 78.9M | -10.0% | 82.6M | — | — | — |
| Equity | — | 499.3M | 287.5M | 250.5M | 160.9M | -31.4% | — | — | — | — |
| Op CF | — | -290.1M | -253.6M | -223.2M | -143.8M | — | -132.6M | — | — | — |
| Inv CF | — | 210.6M | 172.0M | 17.5M | -40.2M | — | — | — | — | — |
| Fin CF | — | 4.9M | 31.6M | 199.7M | 128.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SANA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SANA | Sana Biotechnology, Inc.(you) | $885M | 10 | STRONG SELL |
| OLMA | Olema Pharmaceuticals, Inc. | $1.0B | 10 | STRONG SELL |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.1B | 11 | STRONG SELL |
| 0IL8.L | Kyntra Bio, Inc. | $666M | 10 | STRONG SELL |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 8 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 11 | STRONG SELL |
| INBX | Inhibrx Biosciences, Inc. | $1.2B | 10 | STRONG SELL |
| ODTX | Odyssey Therapeutics, Inc. | $896M | 3 | STRONG SELL |
| ANNX | Annexon, Inc. | $855M | 16 | STRONG SELL |
| AVLN | Avalyn Pharma Inc. | $1.2B | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%